Cognition Therapeutics wins US patent for new crystalline form of zervimesine through 2045
Cognition Therapeutics won a U.S. patent covering a new crystalline form of its lead candidate zervimesine (CT1812). The composition-of-matter protection runs through 2045, with potential FDA-related extension of up to five years. Claims also cover a manufacturing process plus treatment methods for Alzheimer’s disease,